Harrow, Inc. (NASDAQ:HROW) Shares Sold by D.A. Davidson & CO.

D.A. Davidson & CO. lowered its holdings in shares of Harrow, Inc. (NASDAQ:HROW) by 1.7% in the fourth quarter, Holdings Channel reports. The firm owned 60,913 shares of the company’s stock after selling 1,028 shares during the quarter. D.A. Davidson & CO.’s holdings in Harrow were worth $2,044,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Quest Partners LLC acquired a new stake in Harrow during the 3rd quarter worth $29,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Harrow by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock valued at $57,000 after purchasing an additional 227 shares in the last quarter. Hills Bank & Trust Co purchased a new position in shares of Harrow in the 3rd quarter valued at about $107,000. Huntington National Bank purchased a new position in shares of Harrow in the 3rd quarter valued at about $164,000. Finally, Virtu Financial LLC purchased a new position in Harrow during the 3rd quarter valued at about $271,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Stock Performance

Shares of NASDAQ HROW opened at $28.95 on Friday. The company has a 50-day simple moving average of $33.22 and a 200-day simple moving average of $40.06. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. Harrow, Inc. has a 12 month low of $9.30 and a 12 month high of $59.23. The company has a market cap of $1.03 billion, a PE ratio of -30.80 and a beta of 0.69.

Analyst Upgrades and Downgrades

HROW has been the subject of several recent research reports. B. Riley dropped their target price on shares of Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a report on Wednesday, December 4th. HC Wainwright initiated coverage on shares of Harrow in a report on Thursday, February 6th. They set a “buy” rating and a $57.00 price target for the company.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.